These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 35156138)

  • 41. Newer classes of antidiabetes drugs: ophthalmological considerations for GLP-1R agonists, DPP-4 inhibitors, and SGLT-2 inhibitors.
    McReelis KD; Lovshin JA
    Can J Ophthalmol; 2017 Nov; 52 Suppl 1():S4-S7. PubMed ID: 29074013
    [No Abstract]   [Full Text] [Related]  

  • 42. [GLP-1 receptor agonists versus SGLT-2 inhibitors in obese type 2 diabetes patients].
    Marques AR; Jaafar J; de Kalbermatten B; Philippe J
    Rev Med Suisse; 2015 Jun; 11(477):1227-8, 1230-3. PubMed ID: 26211282
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Targeting type 2 diabetes.
    Schwanstecher C; Schwanstecher M
    Handb Exp Pharmacol; 2011; (203):1-33. PubMed ID: 21484565
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Diabetes: Pharmacotherapy for Type 2 Diabetes.
    St Onge E
    FP Essent; 2021 May; 504():22-27. PubMed ID: 33970588
    [TBL] [Abstract][Full Text] [Related]  

  • 45. New Glucose-Lowering Agents for Diabetic Kidney Disease.
    de Vos LC; Hettige TS; Cooper ME
    Adv Chronic Kidney Dis; 2018 Mar; 25(2):149-157. PubMed ID: 29580579
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [The unresolved problems of type 2 diabetes. Diabetology practice].
    Rüssmann HJ
    Pharm Unserer Zeit; 2010 Mar; 39(2):126-32. PubMed ID: 20196045
    [No Abstract]   [Full Text] [Related]  

  • 47. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).
    Thornberry NA; Gallwitz B
    Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):479-86. PubMed ID: 19748065
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sodium-glucose co-transporter-2 inhibitors and epicardial adiposity.
    Yaribeygi H; Maleki M; Butler AE; Jamialahmadi T; Sahebkar A
    Eur J Pharm Sci; 2023 Jan; 180():106322. PubMed ID: 36336279
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of Diabetes Medications Used by Adults With Commercial Insurance vs Medicare Advantage, 2016 to 2019.
    McCoy RG; Van Houten HK; Deng Y; Mandic PK; Ross JS; Montori VM; Shah ND
    JAMA Netw Open; 2021 Feb; 4(2):e2035792. PubMed ID: 33523188
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cardiovascular effects of antidiabetic drugs.
    Sørensen AM; Christensen MB
    Drugs Today (Barc); 2018 Sep; 54(9):547-559. PubMed ID: 30303495
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study.
    Eliasson B; Möller-Goede D; Eeg-Olofsson K; Wilson C; Cederholm J; Fleck P; Diamant M; Taskinen MR; Smith U
    Diabetologia; 2012 Apr; 55(4):915-25. PubMed ID: 22237690
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Linagliptin: a novel xanthine-based dipeptidyl peptidase-4 inhibitor for treatment of type II diabetes mellitus.
    Ghatak SB; Patel DS; Shanker N; Srivastava A; Deshpande SS; Panchal SJ
    Curr Diabetes Rev; 2011 Sep; 7(5):325-35. PubMed ID: 21916836
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacotherapy of hyperglycemia.
    Kulasa KM; Henry RR
    Expert Opin Pharmacother; 2009 Oct; 10(15):2415-32. PubMed ID: 19743938
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Primary care management of type 2 diabetes: a comparison of the efficacy and safety of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.
    Campos C; Unger J
    Postgrad Med; 2021 Nov; 133(8):843-853. PubMed ID: 34416133
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Effects of Novel Antidiabetic Drugs on Albuminuria in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Luo Y; Lu K; Liu G; Wang J; Laurent I; Zhou X
    Clin Drug Investig; 2018 Dec; 38(12):1089-1108. PubMed ID: 30255388
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials.
    Madsbad S; Krarup T; Deacon CF; Holst JJ
    Curr Opin Clin Nutr Metab Care; 2008 Jul; 11(4):491-9. PubMed ID: 18542012
    [TBL] [Abstract][Full Text] [Related]  

  • 57. SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes: BMJ Rapid Recommendation.
    Arnold MJ; Buelt A
    Am Fam Physician; 2022 Jun; 105(6):675-677. PubMed ID: 35704807
    [No Abstract]   [Full Text] [Related]  

  • 58. Clinical use of GLP-1 agonists and DPP4 inhibitors.
    Tuch BE
    Pancreatology; 2016; 16(1):8-9. PubMed ID: 26138513
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Contrasting effects on the risk of macrovascular and microvascular events of antihyperglycemic drugs that enhance sodium excretion and lower blood pressure.
    Packer M
    Diabet Med; 2018 Jun; 35(6):707-713. PubMed ID: 29532519
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with kidney outcomes in patients with type 2 diabetes: A systematic review and network meta-analysis.
    Yang S; He W; Zhao L; Mi Y
    PLoS One; 2022; 17(4):e0267025. PubMed ID: 35421174
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.